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ABSTRACT
Background: IL-33 is known to induce Th2-type cytokine production by various types of cells through its re-
ceptors, ST2 and IL-1RAcP. Polymorphism in the ST2 andor IL-33 genes was found in patients with atopic
dermatitis and asthma, implying that the IL-33ST2 pathway is closely associated with susceptibility to these
diseases. Exposure to allergens through damaged skin is suspected to be a trigger for allergen sensitization,
resulting in development of such allergic disorders as asthma and atopic dermatitis.
Methods: To elucidate the role(s) of the IL-33ST2 pathway in asthma in individuals who had been epicutane-
ously sensitized to an antigen, wild-type and ST2−− mice were epicutaneously sensitized with ovalbumin
(OVA) and then were intranasally challenged with OVA. The degree of airway inflammation, the number of leu-
kocytes and the activities of myeloperoxidase (MPO) and eosinophil peroxidase (EPO) in bronchoalveolar lav-
age fluids (BALFs), The levels of cytokines and chemokines in lungs and OVA-specific IgE levels in sera were
determined by histological analysis, a hemocytometer, colorimetric assay, quantitative PCR or ELISA, respec-
tively.
Results: The number of eosinophils in BALFs, the levels of Th2 cytokines and chemoattractants in the lungs
and OVA-specific IgE in sera from ST2−− mice were significantly reduced compared with wild-type mice. Al-
though the number of neutrophils in BALFs and the pulmonary levels of IL-17 were comparable in both mice,
the levels of MPO activity in BALFs and neutrophil chemoattractants in the lung were reduced in ST2−− mice.
Conclusions: The IL-33ST2 pathway is crucial for Th2-cytokine-mediated eosinophilic, rather than Th17-
cytokine-mediated neutrophilic, airway inflammation in mice that had been epicutaneously sensitized with anti-
gens and then challenged with antigen.
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INTRODUCTION
Several longitudinal epidemiological studies proved
that eczema is the first clinical manifestation of aller-
gic diseases during infancy, followed by the develop-
ment of atopic asthma and rhinitis.1-4 The underlying
mechanisms of allergic disease development remain
unclear, but exposure to allergens through skin dam-
aged by disruption of the epidermal barriers is sus-
pected to be a trigger for sensitization in allergic dis-
orders. In support of this notion, genetic deficiency
for filaggrin, which is crucial for formation of epider-
mal barriers, is considered to be a predisposing factor
for certain allergic diseases such as atopic dermatitis,
asthma and rhinitis.5-8 Notably, filaggrin-deficient
mice develop dermatitis after epicutaneous exposure
to protein antigens.9 In addition, mice that had been
epicutaneously sensitized with an allergen develop al-
lergic airway inflammation after inhalation of the
same allergen.10-13 These findings suggest that epicu-
taneous exposure to antigens due to dysfunctional
epidermal barriers contributes strongly to induction
of allergic diseases.
IL-33, a member of the IL-1 family of cytokines, is
able to induce production of Th2-type cytokines by
various types of cells such as Th2 cells and mast cells
through its ST2 and IL-1RAcP receptors.14 IL-33 is lo-
calized in cell nuclei15 and released by necrotic cells
after tissue injury,16-18 suggesting that it may be re-
leased by damaged skin after scratching, thereby
contributing to the development of allergic disorders.
In support of this, IL-33 mRNAprotein levels are ele-
vated in skin lesions of patients with atopic dermati-
tis.19 Polymorphism of the ST2 andor IL-33 genes
was found in patients with atopic dermatitis, asthma
and rhinitis,20-26 implying an association with disease
severity. However, the role(s) of the IL-33ST2 path-
way in allergic airway inflammation in individuals
who had been epicutaneously sensitized to an antigen
remains unclear. We attempted to elucidate its role
(s) by studies in ST2-deficient mice.
METHODS
MICE
BALBcA wild-type mice were purchased from
Sankyo Lab (Tsukuba, Japan). ST2−− mice (on the
BALBc background) were generated as described
elsewhere.27 Six- to 9-week-old female mice were
used in all experiments. Mice were housed under
specific-pathogen-free conditions at the National Re-
search Institute for Child Health and Development,
and the animal protocols were approved by the Insti-
tutional Review Boards of the National Research In-
stitute for Child Health and Development and The In-
stitute of Medical Science, The University of Tokyo.
EPICUTANEOUS SENSITIZATION
Mice were epicutaneously sensitized with OVA as de-
scribed elsewhere,13 with minor modifications. In
brief, the dorsal skin of mice was shaved with hair
clippers and then stripped 6 times with adhesive cel-
lophane tape (Nichiban, Tokyo, Japan). A patch (Finn
chamber disk; φ8 mm; Smart Practice, Phoenix, AZ,
USA) containing an antigen solution (400 μg of OVA
[grade V; Sigma-Aldrich, St. Louis, MO, USA] in 40 μl
of PBS) or PBS alone (control) was placed on the
tape-stripped skin for 3 days and then removed. One
week later, a fresh patch having the same content
was applied to the same skin site. This cycle was re-
peated three times, resulting in a total of 9 days’ expo-
sure to the patch.
INDUCTION OF ALLERGIC AIRWAY INFLAMMA-
TION
One week after removal of the last patch, each mouse
was intranasally challenged with OVA (200 μg in 20
μl of PBS) or PBS alone for 3 days (one challenge per
day). Twenty-four hours after the last challenge,
bronchoalveolar lavage fluid (BALF) was collected
from each mouse, as described elsewhere.28 The total
cell count and leukocyte profile were determined
with a hemocytometer (Sysmex XT-1800i; Sysmex
Corporation, Hyogo, Japan), as described previ-
ously.29
MEASUREMENT OF MYELOPEROXIDASE (MPO)
AND EOSINOPHIL PEROXIDASE (EPO) ACTIVI-
TIES
MPO and EPO activities were measured as described
elsewhere.28 Recombinant human MPO and EPO
(Calbiochem) were used as standard reagents.
QUANTITATIVE REAL-TIME PCR
Twenty-four hours after the last challenge, the lungs
were harvested. Total RNA in the lung homogenates
was isolated and Quantitative real-time PCR was per-
formed as described elsewhere.29 The mRNA expres-
sion levels were normalized to the GAPDH level in
each sample. PCR primers were designed as shown
in Table 1.
HISTOLOGY
Twenty-four hours after the last challenge, the lungs
were harvested and fixed in Carnoy’s solution. The
fixed tissue was embedded in paraffin and sliced into
5-μm sections, followed by hematoxylin-eosin or peri-
odic acid-Schiff (PAS) staining.
MEASUREMENT OF OVA-SPECIFIC IMMUNO-
GLOBULINS IN SERA
Sera were collected twenty-four hours after the last
challenge. The level of OVA-specific IgE in each se-
rum was determined by ELISA, as described else-
where.30 Anti-OVA mouse IgE (TOS-2), as a standard
OVA-specific IgE, was kindly provided by Dr.
Mamoru Kiniwa (Taiho Pharmaceutical, Saitama, Ja-
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Table　1　Primer designs
Gene Forward (5’-3’) Reverse (5’-3’)
GAPDH                             CCCACTCTTCCACCTTCGATG AGGTCCACCACCCTGTTGCT
ST2 short TCAACCGCCTAGTGAACACACC CAAAGCCCAAAGTCCCATTCTC
IL-33 CAGGCCTTCTTCGTCCTTCAC TCTCCTCCACTAGAGCCAGCTG
IL-4 TCCAAGGTGCTTCGCATATTTT CAGCTTATCGATGAATCCAGGC
IL-5 CCCTCATCCTCTTCGTTGCAT ATGTGATCCTCCTGCGTCCAT
IL-13 GGCAGCAGCTTGAGCACATT GGCATAGGCAGCAAACCATG
IL-17A CCGCAATGAAGACCCTGATAGAT AGAATTCATGTGGTGGTCCAGC
CCL11 GAATCACCAACAACAGATGCAC ATCCTGGACCCACTTCTTCTT
CCL22 ATCCTGGACCCACTTCTTCTT CGGCAGGATTTTGAGGTCCA
CXCL1 CGGCAGGATTTTGAGGTCCA TGAACGTCTCTGTCCCGAGC
CXCL2 AACTGACCTGGAAAGGAGGAGC ACTCTCAGACAGCGAGGCACAT
Fig.　1　Expression of IL-33 and ST2 mRNA was upregulated in the skin after tape stripping. mRNA was isolated 
from the dorsal skin of wild-type mice at the indicated time points after tape stripping. The expression of IL-33 
and ST2 mRNA was determined by quantitative PCR. Data show the mean + SE (n = 4). *P < 0.05 vs. 0 (hours).
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STATISTICS
Unless otherwise specified, the unpaired Student’s t-
test, two-tailed, was used for statistical evaluation of
the results. All results are shown as the mean + SEM.
RESULTS
EXPRESSION OF IL-33 AND ST2 mRNA WAS
UPREGULATED IN THE SKIN AFTER TAPE
STRIPPING
An active form of IL-33 that is localized in the cell nu-
cleus15 is considered to be released by necrotic cells
during tissue injury.16-18 Patients with atopic dermati-
tis scratch inflamed skin lesions, resulting in exacer-
bation of the symptoms due to mechanical skin in-
jury.31 Since increased expression of IL-33 was ob-
served in the lesions of patients with atopic dermati-
tis,19 mechanical skin injury by scratching may result
in release of IL-33, contributing to the disease devel-
opment. Indeed, we found that expression of IL-33
and ST2 mRNA was significantly increased in the
skin of wild-type mice at 3 and 6 hours after tape
stripping, which was used to mimic mechanical skin
injury due to scratching (Fig. 1). These observations
suggest that scratching-induced IL-33 and ST2 pro-
duction may contribute to the pathogenesis of aller-
gic diseases.
ALLERGIC AIRWAY INFLAMMATION WAS AT-
TENUATED IN ST2−− MICE SENSITIZED EPICU-
TANEOUSLY WITH OVA
Allergic airway inflammation was induced by OVA in-
halation in mice that had been epicutaneously sensi-
tized with OVA by tape stripping.10,13 To elucidate the
role of the IL-33ST2 pathway in that setting, we
epicutaneously sensitized BALBc-wild-type (WT)
and ST2−− mice with OVA and then induced airway
inflammation by intranasal challenge with OVA, as
shown in Figure 2. Pulmonary inflammation accom-
panied by eosinophil and neutrophil infiltration, gob-
let cell hyperplasia and mucus secretion, but not epi-
thelial and smooth muscle cell hyperplasia, was ob-
served in epicutaneously OVA-sensitized WT mice af-
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Fig.　2　Experimental protocol.
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ter the last OVA, but not PBS, challenge (Fig. 3A, B).
On the other hand, epicutaneously OVA-sensitized
ST2−− mice showed suppressed eosinophil and neu-
trophil infiltration, but not goblet cell hyperplasia and
mucus secretion, compared with epicutaneously
OVA-sensitized WT mice after the last OVA challenge
(Fig. 3A, B). Consistent with this, the numbers of
cells such as eosinophils, neutrophils and lympho-
cytes in BALFs were significantly increased in both
epicutaneously OVA-sensitized WT and ST2−− mice
after intranasal challenge with OVA in comparison
with after PBS inhalation (Fig. 3C). However, the
total-cell, eosinophil and macrophage, but not lym-
phocyte, counts in BALFs from ST2−− mice were sig-
nificantly reduced compared with WT mice (Fig. 3C).
The levels of EPO activity in BALFs from ST2−− mice
were also decreased in that setting (Fig. 4A). Despite
a slight, but not statistically significant, decrease in
neutrophils in BALFs from ST2−− mice (Fig. 3C), the
level of MPO activity was markedly decreased in
those BALFs compared with BALFs from WT mice
(Fig. 4A). In addition, after the challenge with OVA,
the level of OVA-specific IgE in sera from epicutane-
ously OVA-sensitized ST2−− mice was also signifi-
cantly reduced compared with epicutaneously OVA-
sensitized WT mice (Fig. 4B).
IL-33-ST2 PATHWAY IS REQUIRED FOR Th2-
TYPE, BUT NOT Th17-TYPE, IMMUNE RE-
SPONSES IN MICE AFTER EPICUTANEOUS Ag
SENSITIZATION
Others demonstrated that airway eosinophilia is me-
diated by Th2 cytokines, while airway neutrophilia is
mediated by Th17 cytokines, in mice epicutaneously
sensitized with OVA and then subjected to intranasal
OVA challenge.11,12 Consistent with previous reports,
we observed that-in addition to expression of mRNA
for Th2 cytokines (i.e., IL-4, IL-5 and IL-13) and Th2-
associated chemokines (i.e., CCL11 and CCL22) the
expression of mRNA for IL-17A and neutrophil
chemoattractants (i.e., CXCL1 and CXCL2) in the
lungs from epicutaneously OVA-sensitized WT mice
after the last OVA challenge was significantly in-
creased in comparison with after PBS inhalation (Fig.
5). Consistent with the number of eosinophils and the
level of EPO activity in BALFs, mRNA expression for
IL-4, IL-5, IL-13, CCL11 and CCL22 in the lungs from
epicutaneously OVA-sensitized ST2−− mice was sig-
nificantly decreased compared with epicutaneously
OVA-sensitized WT mice after the last OVA challenge
(Fig. 5). Likewise, expression of mRNA was de-
creased for CXCL1 and CXCL2 but normal for IL-17A
in the lungs from epicutaneously OVA-sensitized
ST2−− mice compared with epicutaneously OVA-
sensitized WT mice after the last OVA challenge (Fig.
5). These observations suggest that the IL-33ST2
pathway is crucial for development of Th2-type im-
mune responses and contributes to, but not is essen-
tial for, the development of Th17-type immune re-
sponses during antigen sensitization due to mechani-
cal skin injury.
DISCUSSION
IL-33 is known to induce secretion of Th2-type cytoki-
nes by various types of cells such as Th2 cells, mast
cells, basophils, eosinophils and innate-type lymphoid
cells (i.e., natural helper cells, nuocytes, MPP2 cells
and ih2 cells) through its ST2 and IL-1RAcP recep-
tors,14,32-36 suggesting involvement of IL-33 in the
pathogenesis of Th2-type allergic disorders. Indeed,
the levels of soluble ST2 proteins and IL-33 mRNA
protein are increased in sera andor tissue specimens
from patients with asthma37-39 and in the lungs of
mice that developed allergic airway inflammation.40,41
Moreover, it is suspected that single-nucleotide poly-
morphisms in the regions of the IL-33 and ST2 genes
may influence susceptibility to allergic disorders.20-26
However, the role of the IL-33ST2 pathway in the de-
velopment of OVA-induced allergic airway inflamma-
tion in mice remains controversial, as reviewed else-
where.14 Following two sensitizations with OVA
emulsified with alum (OVAAlum) and then chal-
lenge by OVA inhalation, respiratory function andor
eosinophilic airway inflammation were observed to be
normal in ST2−− mice42-44 but attenuated in anti-ST2
mAb-treated wild-type mice.45,46 On the other hand,
airway inflammation was attenuated in ST2−− mice
that had been sensitized only once with OVAalum
and then challenged by OVA inhalation.43 The reason
for the discrepancy remains unclear. However, it
might be partially due to an immunomodulatory ef-
fect of alum, which was used as an adjuvant, on the
antigen sensitization. For example, mast cells, B
cells, IgE, IL-1, TNF and CCR8 are not required for
development of OVA-induced airway inflammation in
mice that had been sensitized with OVAalum,
whereas they are essential for that event in mice that
had been sensitized with OVA in the absence of alum,
as reviewed elsewhere.47 In the present study, we
used another asthma-like mouse model in which
mice were sensitized with OVA in the absence of
alum via an epicutaneous route after tape stripping of
the skin. It is known that airway inflammation ob-
served in epicutaneously antigen-sensitized mice is
associated with Th2-type cytokine-mediated eosino-
philia and Th17-type cytokine-mediated neutro-
philia.11 Using that model, we clearly demonstrated
that development of Th2-type allergic airway inflam-
mation was significantly attenuated in epicutaneously
Role of ST2 in Airway Inflammation
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Fig.　3　Pulmonary infl ammation was attenuated in epicutaneous OVA-sensitized ST2−/− mice after OVA challenge. Mice 
were epicutaneously sensitized with OVA, followed by intranasal challenge with OVA or PBS, as shown in Figure 2. Twenty-
four hours after the last OVA or PBS inhalation, the lungs, BAL cells and fl uids, and sera were collected. (A, B) Lung histolo-
gy. H&E (A) and PAS (B) staining. Bar = 100 μm. The data show representative results from 8-12 mice in each experimental 
group, as indicated. (C) The number of BAL cells. The data show the mean + SEM (wild-type [WT] mice: PBS, n = 16, and 
OVA, n = 20; ST2−/− mice: PBS, n = 14, and OVA, n = 20). ***P < 0.001 vs. the corresponding values for PBS-treated mice, 
and ††† P < 0.001 vs. the indicated group.
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Fig.　4　The levels of EPO and MPO activities in BALFs and serum IgE were reduced in epicutane-
ous OVA-sensitized ST2−/− mice after OVA challenge. (A) The levels of EPO and MPO activities in 
BALFs and (B) the levels of OVA-specifi c IgE in sera of the wild-type (WT) and ST2−/− mice used in 
Figure 3B. * P < 0.05 and ***P < 0.001 vs. the corresponding values for PBS-treated mice, and ††† P < 
0.001 vs. the indicated groups.
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OVA-sensitized ST2−− mice after intranasal OVA
challenge (Fig. 3B, 4A, 5), suggesting that the IL-33
ST2 pathway is crucial for induction of Th2-type aller-
gic airway inflammation, especially under adjuvant-
free experimental conditions.
It was recently reported that Th2-type eosinophilic
airway inflammation after OVA inhalation was dra-
matically suppressed in IL-4−− IL-13−− mutant mice
that had been epicutaneously sensitized with OVA,
whereas Th17-type neutrophilic airway inflammation
was exaggerated.12 IL-17 production by T cells can be
inhibited by both IL-4 and IFN-γ,48 suggesting that IL-
4-deficiency resulted in increased IL-17 production
and led to the enhanced IL-17-mediated immune re-
sponses observed in IL-4−− IL-13−− mice. In contrast
to IL-4−− IL-13−− mice,12 we found normal levels of
pulmonary IL-17 mRNA expression and airway neu-
trophilia in epicutaneously OVA-sensitized ST2−−
mice after the last OVA challenge (Fig. 3B, 5). It may
be explained that IL-4 mRNA expression was signifi-
cantly decreased, but not completely abrogated, in
ST2−− mice (Fig. 5).
Despite the normal airway neutrophilia and IL-17
levels described above, the levels of CXCL1 and
CXCL2 mRNA expression and MPO activity were
markedly decreased in lungs and BALFs, respec-
tively, from epicutaneously OVA-sensitized ST2−−
mice after the last OVA challenge(Fig. 4A, 5). This
suggests that the IL-33ST2 pathway may be partially
involved in neutrophil recruitment, independently of
IL-17. Indeed, we previously reported that IL-33 can
directly induce production of neutrophil chemoattrac-
tants (i.e., IL-8) by both endothelial and epithelial
cells.49 However, since the effect of the IL-33ST2
pathway on neutrophil recruitment was less than that
of IL-17, ST2 deficiency may not exert a significant ef-
fect on airway neutrophilia in our experimental sys-
tem.
In summary, we demonstrated that the IL-33ST2
pathway is crucial for Th2-cytokine-mediated eosino-
philic, rather than Th17-cytokine-mediated neutro-
philic, airway inflammation in mice that had been
epicutaneously sensitized with antigen. Our findings
may provide a clue for development of novel thera-
peutics for asthma.
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Fig.　5　The expression levels of Th2 cytokines, but not IL-17A, were reduced in lungs from epicutaneous OVA-sen-
sitized ST2−/− mice after OVA challenge. Twenty-four hours after the last OVA challenge, lungs were harvested from 
the wild-type (WT) and ST2−/− mice used in Figure 3B, and the total mRNA was isolated. The expression of mRNA for 
cytokines and chemokines was determined by quantitative PCR. Data show the mean + SEM (WT mice: PBS, n = 16, 
and OVA, n = 20; ST2−/− mice: PBS, n =14, and OVA, n = 20). *P < 0.05, **P < 0.01 and *** P < 0.001 vs. the corre-
sponding values for PBS-treated mice, and † P < 0.05, †† P < 0.01 and ††† P < 0.001 vs. the indicated groups.
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